Literature DB >> 21267533

[Interdisciplinary treatment of non-small cell lung cancer].

J Dunst1, C Kugler, D Ukena.   

Abstract

At the time of diagnosis of non-small cell lung cancer, about two thirds of the patients manifest tumor disease limited to the lungs without distant metastases. In this group localized tumor spread (stages I and II) can be distinguished from locally advanced spread including lymph node metastases (stages IIIA and B). In stages I and II with sufficient cardiopulmonary function, surgical resection is considered the standard treatment approach. If lobe resection is not possible due to comorbidities or limited pulmonary function, parenchyma-sparing resection or definitive radiotherapy is advocated. Postoperative adjuvant chemotherapy is recommended for individual cases in stage IB and as the standard treatment in stage II. In stages IIIA and IIIB interdisciplinary consultation involving pneumologists/oncologists, surgeons, and radiation oncologists is necessary to reach decisions on treatment recommendations. Generally multiple treatment modalities are employed in these stages, such as induction chemotherapy followed by surgery and subsequent irradiation or simultaneous chemoradiotherapy. These treatment combinations with curative intent should be differentiated from the numerous treatment methods with palliative intent.

Entities:  

Mesh:

Year:  2011        PMID: 21267533     DOI: 10.1007/s00108-010-2700-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  18 in total

1.  Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques.

Authors:  Mark K Ferguson; Amy G Lehman
Journal:  Ann Thorac Surg       Date:  2003-12       Impact factor: 4.330

Review 2.  Treatment of stage IIIA non-small cell lung cancer.

Authors:  Lary A Robinson; Henry Wagner; John C Ruckdeschel
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

Review 3.  ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung.

Authors:  Ramesh S Gopal; Sarita Dubey; Kenneth E Rosenzweig; Joe Yujiao Chang; Roy Decker; Richard M Gewanter; Feng-Ming Kong; Brian E Lally; Corey J Langer; Hoon Ku Lee; Benjamin Movsas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-31       Impact factor: 7.038

Review 4.  The treatment of early-stage disease.

Authors:  Clifford G Robinson; Jeffrey D Bradley
Journal:  Semin Radiat Oncol       Date:  2010-07       Impact factor: 5.934

Review 5.  Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.

Authors:  Naveed Alam; Frances A Shepherd; Timothy Winton; Barbara Graham; David Johnson; Robert Livingston; James Rigas; Marlo Whitehead; Keyue Ding; Lesley Seymour
Journal:  Lung Cancer       Date:  2005-03       Impact factor: 5.705

6.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

7.  [Prevention, diagnosis, therapy, and follow-up of lung cancer].

Authors:  G Goeckenjan; H Sitter; M Thomas; D Branscheid; M Flentje; F Griesinger; N Niederle; M Stuschke; T Blum; K-M Deppermann; J H Ficker; L Freitag; A S Lübbe; T Reinhold; E Späth-Schwalbe; D Ukena; M Wickert; M Wolf; S Andreas; T Auberger; R P Baum; B Baysal; J Beuth; H Bickeböller; A Böcking; R M Bohle; I Brüske; O Burghuber; N Dickgreber; S Diederich; H Dienemann; W Eberhardt; S Eggeling; T Fink; B Fischer; M Franke; G Friedel; T Gauler; S Gütz; H Hautmann; A Hellmann; D Hellwig; F Herth; C P Heussel; W Hilbe; F Hoffmeyer; M Horneber; R M Huber; J Hübner; H-U Kauczor; K Kirchbacher; D Kirsten; T Kraus; S M Lang; U Martens; A Mohn-Staudner; K-M Müller; J Müller-Nordhorn; D Nowak; U Ochmann; B Passlick; I Petersen; R Pirker; B Pokrajac; M Reck; S Riha; C Rübe; A Schmittel; N Schönfeld; W Schütte; M Serke; G Stamatis; M Steingräber; M Steins; E Stoelben; L Swoboda; H Teschler; H W Tessen; M Weber; A Werner; H-E Wichmann; E Irlinger Wimmer; C Witt; H Worth
Journal:  Pneumologie       Date:  2010-03-09

Review 8.  Surgical management of T3 and T4 lung cancer.

Authors:  Costanzo A DiPerna; Douglas E Wood
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

9.  Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.

Authors:  Mitchell Machtay; Kyounghwa Bae; Benjamin Movsas; Rebecca Paulus; Elizabeth M Gore; Ritsuko Komaki; Kathy Albain; William T Sause; Walter J Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-25       Impact factor: 7.038

10.  Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.

Authors:  Jeffrey D Bradley; Issam El Naqa; Robert E Drzymala; Marco Trovo; Griffin Jones; Mary Dee Denning
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-30       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.